People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Shenandoah Therapeutics Inc. | — | Pharma | Series B | $21.5M | $108.2M | 2025 |
| Soltego, Inc. | — | Biotechnology | Series A | $7.3M | $243.7M | 2018 |
Nathanael Gray at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nathanael Gray on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DAVID FISHER | 1 | 4 |
| Irina Erenburg | 1 | 3 |
| Philippe Schaison | 1 | 3 |
| Jim Edwards | 1 | 2 |
| Gary Yeung | 1 | 2 |
| Wendy Young | 1 | 1 |
| Isabella Graef | 1 | 1 |
| Mark Stepka | 1 | 1 |
| Nathanael S Gray | 1 | 1 |
| David S Fisher | 1 | 1 |
| Philippe S Schaison | 1 | 1 |
| Craig S Drill | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.